May 30, 2017 01:23 PM Eastern Daylight Time
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Karius, Inc., a life sciences company focused on conquering infectious
diseases, today announced that new data on the company’s next-generation
sequencing test will be presented at the American Society for
Microbiology’s Microbe 2017 conference taking place at the Ernest N.
Morial Convention Center June 1 – 5 in New Orleans.
Abstracts from four studies of the Karius Digital Culture™ test will be
of Nocardia Cyriacigeorgica from a Deep Pulmonary Infection Using a
Novel Plasma-Based Next Generation Sequencing Assay
by Monica Nayakwadi-Singer, M.D.,University of California-San
Francisco (UCSF) Benioff Children’s Hospital Oakland, on June 3 at
12:15 p.m. CT in Exhibit Hall D
Biopsy for Infectious Diseases: Application of a Next-Generation
Sequencing Cell-Free Plasma Assay to Detect Invasive Fungal Infections
byDavid Hong, M.D., medical director, Karius, Inc., on June 3
at 4:30 p.m. CT in room 207
SEP-SEQ Trial – A Pilot Study Characterizing the Performance of a
Novel Plasma Next-Generation Sequencing Assay to Detect Cell-Free
Microbial DNA in Patients with Sepsis
presented bySimone Thair, Ph.D., Stanford University Medical Center, on
June 4 at 12:15 p.m. CT in Exhibit Hall D
DISCOVER Trial: Application of a Novel Plasma Next-Generation
Sequencing Assay to Detect Cell-Free Microbial DNA in Stem-Cell
Fung, M.D., UCSF,onJune 4 at 12:15 p.m.
CT in Exhibit Hall D
Karius will also be presenting “Beyond the Panel,” an informational
session highlighting the company’s technology platform and how it has
been used by physicians to detect a variety of difficult-to-diagnose
pathogens. The presentation will take place Saturday, June 3 at 1:30
p.m. CT in the Industry and Science Showcase Theater A.
About the Karius Digital Culture™ Test
The Karius Digital Culture™ test applies advanced sequencing and
analytics for the broad and rapid detection of microbial cell-free DNA
through a standard blood draw. Unlike conventional culture and panel
testing methods that test for a narrow range of pathogens, the Karius
test can detect more than 1,250 pathogens. Through Karius’
CAP-accredited and CLIA-certified laboratory service, the test empowers
doctors to diagnose infections, provide more targeted treatment, and
spare patients the pain and risks of invasive biopsies.
About Karius, Inc.
Karius is a life sciences company focused on conquering infectious
diseases through the innovative use of next-generation sequencing to
analyze microbial cell-free DNA. The company’s genomics platform
delivers unprecedented insight into the microbial landscape, providing
clinicians with a comprehensive test capable of identifying more than a
thousand pathogens directly from blood and helping industry accelerate
drug development. For more information visit kariusdx.com
and follow us on Twitter at @kariusdx.